Kewl is a commercial stage Chinese medtech developing a disruptive co-ablation technology (cryoablation and thermal ablation) for the treatment of solid tumor. The device is CE marked and China NMPA approved. The company has raised over $100million from top investors. Their technology used Liquid Nitrogen (vs Argon) for cooling which significantly reduces costs and increased access globally. Looking for distribution partners globally (ex-China).
Click here to receive more information about the Kewl, and reserve its roadshow next month.
BioToChina.org 